A systematic review of positron emission tomography (PET) and positron emission tomography/ computed tomography (PET/CT) for the diagnosis of breast cancer recurrence

Health Technology Assessment

Volumn 14, Issue 50, 2010, Pages 1-120

  Pennant, M ^a   Takwoingi, Y ^a   Pennant, L ^b   Davenport, C ^a   Fry Smith, A ^a   Eisinga, A ^c   Andronis, L ^a   Arvanitis, T ^a   Deeks, J ^a   Hyde, C ^d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NATIONAL HEALTH SERVICE   (United Kingdom)

^c UK COCHRANE CENTRE   (United Kingdom)

^d UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; INTERMETHOD COMPARISON; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; SENSITIVITY AND SPECIFICITY; WHOLE BODY PET;

BREAST NEOPLASMS; CONFIDENCE INTERVALS; FEMALE; GREAT BRITAIN; HUMANS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84883742459     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta14500     Document Type: Article

References (62)

1. Office for National Statistics. Breast cancer incidence, mortality and survival. London; ONS; 2009.
2. The BMJ Publishing Group. Clinical evidence, Issue 15. London: The BMJ Publishing Group; 2006.
3. National Institute for Health and Clinical Excellence. CG80 Early and locally advanced breast cancer: full guideline. London: NICE; 2009. http:// guidance.nice.org.uk/CG80/Guidance/pdf/English (accessed January 2010).
4. Elder EE, Kennedy CW, Gluch L, Carmalt HL, Janu NC, Joseph MG, et al. Patterns of breast cancer relapse. Eur J Surg Oncol 2006; 32(9):922-7.
5. Lamerato L, Havstad S, Gandhi S, Jones D, Nathanson D. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer 2006;106(9):1875-82.
6. Barentsz J, Takahashi S, Oyen W, Mus R, De MP, Reznek R, et al. Commonly used imaging techniques for diagnosis and staging. J Clin Oncol 2006;24(20):3234-44.
7. Schnall M, Rosen M. Primer on imaging technologies for cancer. J Clin Oncol 2006;24 (20):3225-33.
8. Love C, Din AS, Tomas MB, Kalapparambath TP, Palestro CJ. Radionuclide bone imaging: an illustrative review. Radiographics 2003;23(2):341-58.
9. Hayes DF. Tumor markers for breast cancer. Ann Oncol 1993;4(10):807-19.
10. Belli P, Costantini M, Romani M, Marano P, Pastore G. Magnetic resonance imaging in breast cancer recurrence. Breast Cancer Res Treat 2002;73(3):223-35.
11. Engelhard K, Hollenbach HP, Wohlfart K, von IE, Fellner FA. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 2004;14(1):99-105.
12. Walker R, Kessar P, Blanchard R, Dimasi M, Harper K, DeCarvalho V, et al. Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging 2000;11(4):343-50.
13. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231(2):305-32.
14. Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 2003;23(2):315-40.
15. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006;238(2):405-22.
16. The Royal College of Radiologists. PET-CT in the UK: A strategy for development and integration of a leading edge technology within routine clinical practice. London: RCR; 2005.
17. National Institute for Health and Clinical Excellence. CG81 Advanced breast cancer: diagnosis and treatment. London: NICE; 2009.
18. Samson D, Redding Flamm C, Aronson N. FDG positron emission tomography for evaluating breast cancer. Blue Cross and Blue Shield Association, Technology Evaluation Center. 2001:95. URL: http://cms.gov/coverage/download/id71.pdf.
19. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005;90(2):105-12.
20. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
21. Schelbert HR, Hoh CK, Royal HD, Brown M, Dahlbom MN, Dehdashti F, et al. Procedure guideline for tumor imaging using fluorine-18- FDG. Society of Nuclear Medicine. J Nucl Med 1998;39(7):1302-5.
22. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58(10):982-90.
23. Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol 2006;59(12):1331-2.
24. Abe K, Sasaki M, Kuwabara Y, Koga H, Baba S, Hayashi K, et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005;19(7):573-9.
25. Aide N, Huchet V, Switsers O, Heutte N, Delozier T, Hardouin A, et al. Influence of CA 15-3 blood level and doubling time on diagnostic performances of 18F-FDG PET in breast cancer patients with occult recurrence. Nucl Med Commun 2007;28(4):267-72.
26. Bender H, Kirst J, Palmedo H, Schomburg A, Wagner U, Ruhlmann J, et al. Value of 18-fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997;17(3B):1687-92.
27. Dirisamer A, Halpern BS, Flory D, Wolf F, Beheshti M, Mayerhoefer ME, et al. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur J Radiol 2010;73(2):294-9.
28. Fueger BJ, Weber WA, Quon A, Crawford TL, len-Auerbach MS, Halpern BS, et al. Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 2005;7(5):369-76.
29. Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003;38(5):250-6.
30. Goerres GW, Michel SCA, Fehr MK, Kaim AH, Steinert HC, Seifert B, et al. Follow-up of women with breast cancer: Comparison between MRI and FDG PET. Eur Radiol 2003; 13(7):1635-44.
31. Guillemard S, Eberle Pouzeratte MC, Lamy P-J, Romieu G, Rossi M, Artus JC. 18FDG PET/CT and CA 15-3 in the early diagnosis of recurrent breast cancer. [French]. Méd Nucl 2006;30(4):209-16.
32. Hathaway PB, Mankoff DA, Maravilla KR, Austin-Seymour MM, Ellis GK, Gralow JR, et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 1999;210(3):807-14.
33. Haug AR, Schmidt GP, Klingenstein A, Heinemann V, Stieber P, Priebe M, et al. F-18- fluoro-2-deoxyglucose positron emission tomography/computed tomography in the followup of breast cancer with elevated levels of tumor markers. J Comput Assist Tomogr 2007;31(4):629-34.
34. Hubner KF, Smith GT, Thie JA, Bell JL, Nelson HS, Hanna WT. The potential of F-18- FDG PET in breast cancer. Detection of primary lesions, axillary lymph node metastases, or distant metastases. Clin Positron Imaging 2000;3(5):197-205.
35. Kamel EM, Wyss MT, Fehr MK, von Schulthess GK, Goerres GW. [18F]-fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 2003;129(3):147-53.
36. Kim T-S, Moon WK, Lee D-S, Chung J-K, Lee MC, Youn Y-K, et al. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg 2001;25(7):829-34.
37. Lin W-Y, Tsai S-C, Cheng K-Y, Yen R-F, Kao C-H. Fluorine-18 FDG-PET in detecting local recurrence and distant metastases in breast cancer - Taiwanese experiences. Cancer Invest 2002;20(5-6):725-9.
38. Liu CS, Shen YY, Lin CC, Yen RF, Kao CH, Liu CS, et al. Clinical impact of [(18)F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report. Jpn J Clin Oncol 2002;32(7):244-7.
39. Lonneux M, Borbath I, I, Berliere M, Kirkove C, Pauwels S. The place of whole-body pet fdg for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 2000;3(2):45-9.
40. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK, et al. Accuracy of wholebody fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39(3):431-5.
41. Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T, et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Medi Commun 2001;22(8):875-9.
42. Pecking AP, Corone-Mechelany C, Alberini JL, Gutman F, Sarandi F, Bertrand-Kermorgant F, et al. Positrons Emission Tomography (PET) using 18FDG and occult diseases in cancerology: the experiment of the Rene Huguenin Center. [French]. Immunoanal Biol Spéc 2004;19(5):269-73.
43. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O, Radan L, et al. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006;107(11):2545-51.
44. Raileanu I, Grahek D, Montravers F, Kerrou K, Aide N, Younsi N, et al. Comparison of [18F]- fluorodeoxyglucose positron emission tomography and technetium bisphosphonate bone scintigraphy to detect bone metastases in patients with breast cancer. [French]. Méd Nucl 2004;28(7):297-303.
45. Santiago JF, Gonen M, Yeung H, Macapinlac H, Larson S, Santiago JFY, et al. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging 2006;50(1):61-7.
46. Schmidt GP, Baur-Melnyk A, Haug A, Heinemann V, Bauerfeind I, Reiser MF, et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol 2008;65(1):47-58.
47. Suarez M, Perez-Castejon MJ, Jimenez A, Domper M, Ruiz G, Montz R, et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med Mol Imaging 2002;46(2):113-21.
48. Veit-Haibach P, Antoch G, Beyer T, Stergar H, Schleucher R, Hauth EA, et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J of Radiol 2007;80(955):508-15.
49. Vranjesevic D, Filmont JE, Meta J, Silverman DH, Phelps ME, Rao J, et al. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 2002;43(3):325-9.
50. Wolfort RM, Li BDL, Johnson LW, Turnage RH, Lilien D, Ampil F, et al. The role of whole-body fluorine-18-FDG positron emission tomography in the detection of recurrence in symptomatic patients with stages II and III breast cancer. World J Surg 2006;30(8):1422-7.
51. Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC, et al. Comparing whole body (18)F-2- deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002;128(6):325-8.
52. Yap CS, Seltzer MA, Schiepers C, Gambhir SS, Rao J, Phelps ME, et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med 2001;42(9):1334-7.
53. Belohlavek O, Kantorova I. Influence of positron emission tomography (PET) on therapeutic decision at breast cancer - Preliminary report. [Czech]. Klinicka Onkologie 2002;15(5):189-91.
54. Grahek D, Montravers F, Kerrou K, Aide N, Lotz JP, Talbot JN, et al. [18F]FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nucl Med Mol Imaging 2004;31(2):179-88.
55. Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 2004;183(2):479-86.
56. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003;139(11):879-92.
57. Shie P, Cardarelli R, Brandon D, Erdman W, Abdulrahim N. Meta-analysis: comparison of F-18 Fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med 2008;33(2):97-101.
58. Smith IC, Ogston KN, Whitford P, Smith FW, Sharp P, Norton M, et al. Staging of the axilla in breast cancer: Accurate in vivo assessment using positron emission tomography with 2-(fluorine- 18)-fluoro-2-deoxy-D- glucose. Ann Surg 1998;228(2):220-7.
59. Van der Hoeven JJ, Krak NC, Hoekstra OS, Comans EF, Boom RP, Van GD, et al. 18F-2-fluoro- 2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004;22(7):1253-9.
60. Rostom AY, Powe J, Kandil A, Ezzat A, Bakheet S, El-Khwsky F, et al. Positron emission tomography in breast cancer: A clinicopathological correlation of results. Br J Radiol 1999;72:1064-8.
61. Dose J, Bleckmann C, Bachmann S, Bohuslavizki KH, Berger J, Jenicke L, et al. Comparison of fluorodeoxyglucose positron emission tomography and 'conventional diagnostic procedures' for the detection of distant metastases in breast cancer patients. Nucl Med Commun 2002;23(9):857-64.
62. Siggelkow W, Zimny M, Faridi A, Petzold K, Buell U, Rath W. The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res 2003;23(2C):1859-67.